Predictors of hepatotoxicity in patients receiving CDK4/6 inhibitors: A real-world cohort study.

Ertaş H, Caner B, Ulaş A, Koç Y

Open source

DOI
10.1177/10781552261447894
Published
2026 May 14
Container
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1177/10781552261447894,
  title = {Predictors of hepatotoxicity in patients receiving CDK4/6 inhibitors: A real-world cohort study.},
  author = {Ertaş H and Caner B and Ulaş A and Koç Y},
  year = {2026},
  journal = {Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners},
  doi = {10.1177/10781552261447894},
  url = {https://doi.org/10.1177/10781552261447894}
}

RIS

TY  - JOUR
TI  - Predictors of hepatotoxicity in patients receiving CDK4/6 inhibitors: A real-world cohort study.
AU  - Ertaş H
AU  - Caner B
AU  - Ulaş A
AU  - Koç Y
PY  - 2026
JO  - Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
DO  - 10.1177/10781552261447894
UR  - https://doi.org/10.1177/10781552261447894
ER  - 

APA

H, E., B, C., A, U., & Y, K. (2026). Predictors of hepatotoxicity in patients receiving CDK4/6 inhibitors: A real-world cohort study.. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. https://doi.org/10.1177/10781552261447894

Source records